1. Interleukin-37 promotes colitis-associated carcinogenesis via SIGIRR-mediated cytotoxic T cells dysfunction
- Author
-
Zhen Wang, Fan-lian Zeng, Ya-wen Hu, Xiao-yan Wang, Fu-lei Zhao, Pei Zhou, Jing Hu, Yuan-yuan Xiao, Zhong-lan Hu, Ming-feng Guo, Xiao-qiong Wei, Xiao Liu, Nong-yu Huang, Jun Zhang, Shu-wen Chen, Juan Cheng, Hua-ping Zheng, Hong Zhou, Qi-xiang Zhao, Chen Zhang, Yan Hao, Song Zou, Yi-yue Gui, Jia-dong Yu, Lin-na Gu, Cheng-cheng Yue, Hao-zhou Zhang, Wen-ling Wu, Yi-fan Zhou, Xi-kun Zhou, Guo-bo Shen, Xiu Teng, and Jiong Li
- Subjects
Medicine ,Biology (General) ,QH301-705.5 - Abstract
Abstract Interleukin-37b (hereafter called IL-37) was identified as fundamental inhibitor of natural and acquired immunity. The molecular mechanism and function of IL-37 in colorectal cancer (CRC) has been elusive. Here, we found that IL-37 transgenic (IL-37tg) mice were highly susceptible to colitis-associated colorectal cancer (CAC) and suffered from dramatically increased tumor burdens in colon. Nevertheless, IL-37 is dispensable for intestinal mutagenesis, and CRC cell proliferation, apoptosis, and migration. Notably, IL-37 dampened protective cytotoxic T cell-mediated immunity in CAC and B16-OVA models. CD8+ T cell dysfunction is defined by reduced retention and activation as well as failure to proliferate and produce cytotoxic cytokines in IL-37tg mice, enabling tumor evasion of immune surveillance. The dysfunction led by IL-37 antagonizes IL-18–induced proliferation and effector function of CD8+ T cells, which was dependent on SIGIRR (single immunoglobulin interleukin-1 receptor-related protein). Finally, we observed that IL-37 levels were significantly increased in CRC patients, and positively correlated with serum CRC biomarker CEA levels, but negatively correlated with the CD8+ T cell infiltration in CRC patients. Our findings highlight the role of IL-37 in harnessing antitumor immunity by inactivation of cytotoxic T cells and establish a new defined inhibitory factor IL-37/SIGIRR in cancer-immunity cycle as therapeutic targets in CRC.
- Published
- 2022
- Full Text
- View/download PDF